Updated: January 20, 2026

For Healthcare Providers Finding Medications

How to Help Your Patients Find Mavyret in Stock: A Provider's Guide

Author

Peter Daggett

Summarize with AI

Why Patients Struggle to Fill Mavyret
Pre-Prescription Checklist: Setting Up for Success
Streamlining the Prior Authorization Process
Routing to the Right Pharmacy
Financial Assistance Pathways for Patients
Recommending medfinder to Patients Who Still Can't Locate Mavyret

A practical provider's guide to helping hepatitis C patients access Mavyret in 2026—from PA workflows and specialty pharmacy routing to financial assistance programs.

Prescribing Mavyret (glecaprevir/pibrentasvir) is the first step toward curing a patient of hepatitis C. Getting the drug into their hands is often the harder part. This guide is designed to give you practical, actionable strategies to minimize delays and help your patients successfully fill their Mavyret prescription.

Why Patients Struggle to Fill Mavyret

Despite not being in a national shortage, Mavyret has some of the most complex dispensing logistics of any oral outpatient medication. The primary barriers are:

Prior authorization (PA): Required by most commercial and Medicare payers; takes 3–14+ days without proactive management

Specialty pharmacy mandate: Many plans require specialty pharmacy dispensing; patients routed to retail pharmacies get rejected or wait for drug ordering

Cost: Over $14,000 cash price per 8-week course creates access barriers for uninsured/underinsured patients

HBV screening requirement: Prescribers must screen for HBV co-infection (HBsAg, anti-HBc) before prescribing—missing this step can delay dispensing

Pre-Prescription Checklist: Setting Up for Success

Before sending the prescription, complete the following:

Confirm HCV genotype and baseline viral load (required for PA)

Document liver fibrosis stage (FIB-4 index, fibroscan, or biopsy)

Test for HBsAg and anti-HBc (boxed warning requirement)

Review medication list for Mavyret contraindications (atazanavir, rifampin) and interactions (statins, antiepileptics, cyclosporine, St. John's wort)

Confirm hepatic function (Child-Pugh class A required)

Determine correct treatment duration (8 weeks most common; 12–16 weeks for some treatment-experienced patients)

Streamlining the Prior Authorization Process

PA submission should happen the same day you make the prescribing decision—not when the patient attempts to fill. Most specialty pharmacies offer dedicated PA submission support: once you send the prescription to their hub, they'll complete the PA process on your behalf.

If a PA is denied, the common reasons are:

Missing lab documentation (genotype, viral load, liver labs)

Step therapy requirement not satisfied (payer wants generic first-line)

Payer has not yet updated criteria to include acute HCV indication (if prescribing for newly diagnosed acute infection)

For appeals, a peer-to-peer review request with the payer's medical director is often the fastest path to approval. AASLD/IDSA guidelines explicitly recommend Mavyret as a first-line option, which supports your clinical rationale.

Routing to the Right Pharmacy

AbbVie's HUB program can assist with specialty pharmacy routing. When you call 1-877-628-9738, they can identify the contracted specialty pharmacy for your patient's plan and facilitate the transfer. The main specialty pharmacy networks for Mavyret are:

Accredo (Express Scripts / Cigna plans)

CVS Specialty (Aetna plans, CVS Caremark plans)

Walgreens Specialty (many commercial plans)

Optum Rx (UnitedHealthcare plans)

Financial Assistance Pathways for Patients

For patients who cannot afford Mavyret:

Commercially insured: Mavyret Savings Card reduces copay to as low as $5/month (up to $12,000 lifetime maximum). Eligibility at mavyret.com/cost or call 1-877-628-9738.

Uninsured/underinsured: myAbbVie Assist program provides free Mavyret to eligible patients. Call 1-800-222-6885 or visit AbbVie.com/PatientAccessSupport.

Medicare patients: The HealthWell Foundation Hepatitis C Fund (1-800-675-8416) and Good Days Program (1-877-968-7233) can help with Part D cost-sharing.

Recommending medfinder to Patients Who Still Can't Locate Mavyret

For patients who have cleared the PA and insurance hurdles but still can't locate a local pharmacy with Mavyret in stock, recommend medfinder.com/providers. medfinder contacts pharmacies near the patient to identify who has the medication in stock and can fill the prescription. It works for Mavyret and other specialty medications. For more on managing access issues, see our post on what providers need to know about Mavyret access in 2026.

Frequently Asked Questions

Per Mavyret's boxed warning, you must test all patients for current or prior HBV infection before initiating treatment. This requires measuring hepatitis B surface antigen (HBsAg) and hepatitis B core antibody (anti-HBc). Patients with evidence of HBV infection must be monitored for hepatitis flare or HBV reactivation during HCV treatment and post-treatment follow-up.

The most efficient approach is to route the prescription directly to a specialty pharmacy that handles Mavyret—they typically have PA submission teams that can manage the process on your behalf with complete documentation. Alternatively, use AbbVie's HUB program (1-877-628-9738) which provides dedicated PA support for Mavyret prescriptions.

Yes. Telehealth providers who are licensed in the patient's state and have access to the necessary lab results can prescribe Mavyret. The prescription must include all elements required for specialty pharmacy dispensing and PA approval. Some telehealth platforms specialize in HCV treatment and have established specialty pharmacy relationships.

File a formal appeal with clinical documentation, including AASLD/IDSA guidelines supporting Mavyret as first-line therapy. Request a peer-to-peer review with the payer's medical director. If the denial is based on step therapy, document why alternatives are clinically inappropriate (e.g., drug interactions with sofosbuvir-based regimens, history of genotype requiring Mavyret's specific coverage, or 8-week duration necessity for adherence).

Yes. No dose adjustment is required for buprenorphine/naloxone or methadone when used concomitantly with Mavyret, per the prescribing information. Mavyret can be an excellent option for patients with HCV who are also on MAT, as the 8-week treatment duration can improve adherence in this population.

Medfinder Editorial Standards

Medfinder's mission is to ensure every patient gets access to the medications they need. We are committed to providing trustworthy, evidence-based information to help you make informed health decisions.

Read our editorial standards